@article{799f15ea7341421cbe0d01af0c76ba14,
title = "Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study",
author = "{Canadian Immunization Monitoring Program, Active (IMPACT) Investigators} and Ricketson, {Leah J.} and Bettinger, {Julie A.} and Manish Sadarangani and Halperin, {Scott A.} and Kellner, {James D.}",
note = "Funding Information: This surveillance activity is conducted by the Canadian Immunization Monitoring Program Active (IMPACT) network of paediatric investigators and managed by the Canadian Paediatric Society (CPS). CPS receives ongoing funding from the Public Health Agency of Canada's (PHAC's) Centre for Immunization and Respiratory Infectious Diseases (CIRID) for Invasive Pneumococcal Disease surveillance. Funding for Invasive Pneumococcal Disease Surveillance for 2002-2005 was provided through an unrestricted grant by Wyeth pharmaceuticals. Funding Information: The authors gratefully acknowledge the expert assistance of the Monitor Liaisons (Annick Audet), IMPACT nurse monitors, staff of the IMPACT Data Center (Kim Marty, Jen Mark) and the Canadian Paediatric Society (Melanie Laffin). This surveillance activity is conducted by the Canadian Immunization Monitoring Program Active (IMPACT) network of paediatric investigators and managed by the Canadian Paediatric Society (CPS). CPS receives ongoing funding from the Public Health Agency of Canada's (PHAC's) Centre for Immunization and Respiratory Infectious Diseases (CIRID) for Invasive Pneumococcal Disease surveillance. Funding for Invasive Pneumococcal Disease Surveillance for 2002-2005 was provided through an unrestricted grant by Wyeth pharmaceuticals. JAB: none. MS: is supported via salary awards from the BC Children's Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. SH: has received funding for clinical trials and has served on ad hoc advisory boards for Pfizer, the manufacturer of PCV7 and PCV13, unrelated to pneumococcal disease. JK: has been an investigator on projects funded by GlaxoSmithKline, Merck, and Pfizer. All funds have been paid to his institute, and he has not received any personal payments. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = apr,
day = "26",
doi = "10.1016/j.vaccine.2022.03.048",
language = "English",
volume = "40",
pages = "2733--2740",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "19",
}
